EQS-News: Immunic, Inc.: Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis
Issuer: Immunic, Inc. / Key word(s): Study results/Strategic Company Decision Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe
Source: finanznachrichten.de
